G Gaudernack
Overview
Explore the profile of G Gaudernack including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
152
Citations
2189
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Almasbak H, Walseng E, Kristian A, Myhre M, Suso E, Munthe L, et al.
Gene Ther
. 2015 Feb;
22(5):391-403.
PMID: 25652098
Cancer therapy with T cells expressing chimeric antigen receptors (CARs) has produced remarkable clinical responses in recent trials, but also severe side effects. Whereas most protocols use permanently reprogrammed T...
2.
Adamczak M, Hoel H, Gaudernack G, Barbasz J, Szczepanowicz K, Warszynski P
Colloids Surf B Biointerfaces
. 2011 Nov;
90:211-6.
PMID: 22078925
The aim of this work was to encapsulate the CdTe quantum dots within the nanocapsules that were prepared by the layer-by-layer adsorption of polyelectrolytes. Two different polyelectrolyte pairs were used...
3.
Torfoss D, Sandstad B, Mollnes T, Hoiby E, Holte H, Bjerner J, et al.
Scand J Immunol
. 2011 Sep;
74(6):632-9.
PMID: 21883353
We evaluated inflammatory markers in febrile neutropenic lymphoma patients undergoing high-dose chemotherapy with autologous stem cell support. Based on MASCC scores, our patients had a low risk of serious complications...
4.
Abrahamsen I, Stronen E, Walchli S, Johansen J, Kjellevoll S, Kumari S, et al.
Leukemia
. 2010 Sep;
24(11):1901-9.
PMID: 20844564
The possibility that allogeneic T cells may be targeted to leukemia has important therapeutic implications. As most tumor antigens represent self-proteins, high-avidity tumor-specific T cells are largely deleted from the...
5.
Szczepanowicz K, Hoel H, Szyk-Warszynska L, Bielanska E, Bouzga A, Gaudernack G, et al.
Langmuir
. 2010 Jul;
26(15):12592-7.
PMID: 20604580
The aim of this work was to develop a novel method of preparation of loaded nanosize capsules based on liquid core encapsulation by biocompatible polyelectrolyte (PE) multilayer adsorption, with or...
6.
Stronen E, Abrahamsen I, Gaudernack G, Walchli S, Munthe E, Buus S, et al.
Scand J Immunol
. 2009 Mar;
69(4):319-28.
PMID: 19284496
Most tumour-associated antigens (TAA) are non-mutated self-antigens. The peripheral T cell repertoire is devoid of high-avidity TAA-specific cytotoxic T lymphocytes (CTL) due to self-tolerance. As tolerance is major histocompatibility complex-restricted,...
7.
Copier J, Dalgleish A, Britten C, Finke L, Gaudernack G, Gnjatic S, et al.
Eur J Cancer
. 2009 Jan;
45(8):1424-31.
PMID: 19167214
A series of cancer vaccines have been evaluated in clinical trials with encouraging results, but the demonstration of clinical benefit in confirmatory studies has so far proven to be difficult....
8.
Jarnjak-Jankovic S, Saeboe-Larssen S, Kvalheim G, Gaudernack G
Cytotherapy
. 2007 Sep;
9(6):587-92.
PMID: 17882723
Background: The use of mRNA in vaccine studies has generally been through loading or transfection of immature DC followed by a maturation step. A recent study has suggested that this...
9.
Bernhardt S, Gjertsen M, Trachsel S, Moller M, Eriksen J, Meo M, et al.
Br J Cancer
. 2006 Oct;
95(11):1474-82.
PMID: 17060934
Patients with inoperable pancreatic cancer have a dismal prognosis with a mean life expectancy of 3-6 months. New treatment modalities are thus urgently needed. Telomerase is expressed in 85-90% of...
10.
Kyte J, Mu L, Aamdal S, Kvalheim G, Dueland S, Hauser M, et al.
Cancer Gene Ther
. 2006 May;
13(10):905-18.
PMID: 16710345
We have developed an individualized melanoma vaccine based on transfection of autologous dendritic cells (DCs) with autologous tumor-mRNA. Dendritic cells loaded with complete tumor-mRNA may generate an immune response against...